lulizumab pegol

Ligand id: 8460

Name: lulizumab pegol

No information available.
Summary of Clinical Use
A Phase II clinical trial in patients with systemic lupus erythematosus (SLE) is underway (June 2015).
Mechanism Of Action and Pharmacodynamic Effects
CD28 is reported to be involved in the activation T-cells [1,4], which are important drivers of autoimmunity. T cells with no CD28 exhibit impaired T-helper 2 (Th2) responses indicating that CD28 is required for the initiation of the T cell response to antigen [1]. Blockade of CD28 with lulizumab blocks T cell activation, and due to the antibody structure actually drives the T cells in to a state of immune tolerance (anergy) [3].